SIRION Biotech GmbH enables its customers to advance the field of gene therapy through multiple proprietary viral vector platforms. The company today announced that its Chief Technology Officer, Christian Thirion, Ph.D., yesterday participated on a panel with leading gene therapy industry experts covering the regulatory needs in clinical development at the Piper Jaffray GenomeRx Symposium at the Yale Club in New York City.
"It's an honor to be part of such distinguished panel as the field of gene therapy continues to deliver important advances to patients. At SIRION, we see our role evolving as critical viral vector supplier across multiple proprietary platforms, said Chrisitian Thirion, Ph.D., Chief Technology Officer."
"It's an honor to be part of such distinguished panel as the field of gene therapy continues to deliver important advances to patients. At SIRION, we see our role evolving as critical viral vector supplier across multiple proprietary platforms, said Chrisitian Thirion, Ph.D., Chief Technology Officer."
